These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 1836100)

  • 21. Early preventive treatment of left ventricular dysfunction following myocardial infarction: optimal timing and patient selection.
    Sharpe N
    Am J Cardiol; 1991 Nov; 68(14):64D-69D. PubMed ID: 1836098
    [TBL] [Abstract][Full Text] [Related]  

  • 22. L-arginine therapy in acute myocardial infarction: the Vascular Interaction With Age in Myocardial Infarction (VINTAGE MI) randomized clinical trial.
    Schulman SP; Becker LC; Kass DA; Champion HC; Terrin ML; Forman S; Ernst KV; Kelemen MD; Townsend SN; Capriotti A; Hare JM; Gerstenblith G
    JAMA; 2006 Jan; 295(1):58-64. PubMed ID: 16391217
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevention of events with angiotensin-converting enzyme inhibition (the PEACE study design). Prevention of Events with Angiotensin-Converting Enzyme Inhibition.
    Pfeffer MA; Domanski M; Rosenberg Y; Verter J; Geller N; Albert P; Hsia J; Braunwald E
    Am J Cardiol; 1998 Aug; 82(3A):25H-30H. PubMed ID: 9719019
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Left ventricular remodeling and ventricular arrhythmias after myocardial infarction.
    St John Sutton M; Lee D; Rouleau JL; Goldman S; Plappert T; Braunwald E; Pfeffer MA
    Circulation; 2003 May; 107(20):2577-82. PubMed ID: 12732606
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of the effects of losartan and captopril on mortality in patients after acute myocardial infarction: the OPTIMAAL trial design. Optimal Therapy in Myocardial Infarction with the Angiotensin II Antagonist Losartan.
    Dickstein K; Kjekshus J
    Am J Cardiol; 1999 Feb; 83(4):477-81. PubMed ID: 10073846
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Progressive ventricular dilation in experimental myocardial infarction and its attenuation by angiotensin-converting enzyme inhibition.
    Pfeffer JM
    Am J Cardiol; 1991 Nov; 68(14):17D-25D. PubMed ID: 1836094
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Effects of ramipril and spironolactone on ventricular remodeling after acute myocardial infarction: randomized and double-blind study].
    Rodríguez JA; Godoy I; Castro P; Quintana JC; Chávez E; Yovanovich J; Corbalán R; Chávez A
    Rev Med Chil; 1997 Jun; 125(6):643-52. PubMed ID: 9515282
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effects of early captopril treatment on left ventricular volumes and function in patients with and without depressed global ejection fraction after acute myocardial infarction.
    Kyriakidis MK; Petropoulakis PN; Georgiou EK; Marakas SA; Michalopoulos DA; Antonopoulos AA; Proukakis CC; Toutouzas PK
    Eur Heart J; 1993 Dec; 14(12):1692-700. PubMed ID: 8131769
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chronic kidney disease, cardiovascular risk, and response to angiotensin-converting enzyme inhibition after myocardial infarction: the Survival And Ventricular Enlargement (SAVE) study.
    Tokmakova MP; Skali H; Kenchaiah S; Braunwald E; Rouleau JL; Packer M; Chertow GM; Moyé LA; Pfeffer MA; Solomon SD
    Circulation; 2004 Dec; 110(24):3667-73. PubMed ID: 15569840
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ejection fraction by radionuclide ventriculography and contrast left ventriculogram. A tale of two techniques. SAVE Investigators. Survival and Ventricular Enlargement.
    Ureña PE; Lamas GA; Mitchell G; Flaker GC; Smith SC; Wackers FJ; McEwan P; Pfeffer MA
    J Am Coll Cardiol; 1999 Jan; 33(1):180-5. PubMed ID: 9935027
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mechanisms involved in cardiac enlargement and congestive heart failure development after acute myocardial infarction.
    Kleber FX; Nussberger J; Niemöller L; Doering W
    Cardiology; 1992; 81(4-5):213-20. PubMed ID: 1301246
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recovery of ventricular function after myocardial infarction in the reperfusion era: the healing and early afterload reducing therapy study.
    Solomon SD; Glynn RJ; Greaves S; Ajani U; Rouleau JL; Menapace F; Arnold JM; Hennekens C; Pfeffer MA
    Ann Intern Med; 2001 Mar; 134(6):451-8. PubMed ID: 11255520
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of diabetes on mortality in patients with myocardial infarction and left ventricular dysfunction.
    Murcia AM; Hennekens CH; Lamas GA; Jiménez-Navarro M; Rouleau JL; Flaker GC; Goldman S; Skali H; Braunwald E; Pfeffer MA
    Arch Intern Med; 2004 Nov; 164(20):2273-9. PubMed ID: 15534166
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarction.
    Solomon SD; Skali H; Anavekar NS; Bourgoun M; Barvik S; Ghali JK; Warnica JW; Khrakovskaya M; Arnold JM; Schwartz Y; Velazquez EJ; Califf RM; McMurray JV; Pfeffer MA
    Circulation; 2005 Jun; 111(25):3411-9. PubMed ID: 15967846
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Captopril. A review of its pharmacology and therapeutic efficacy after myocardial infarction and in ischaemic heart disease.
    Plosker GL; McTavish D
    Drugs Aging; 1995 Sep; 7(3):226-53. PubMed ID: 8535052
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Physical working capacity after acute myocardial infarction in patients with low ejection fraction and effect of captopril.
    Hartley LH; Flaker G; Basta L; Menapace F; Goldman S; Davis B; Hamm P; Lamas G; Moye L; Wun CC
    Am J Cardiol; 1995 Nov; 76(12):857-60. PubMed ID: 7484820
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Left ventricular dilatation following myocardial infarction: clinical course and potential for therapy.
    Lamas GA
    Cardiology; 1989; 76(2):112-21. PubMed ID: 2525955
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Effect of ACE-inhibitors on left ventricular remodeling after acute anterior or posterior myocardial infarct. Cine- magnetic resonance tomography study].
    Konermann M; Odenthal HJ; Altmann C; Laschewski F; Rawert B; Trappe HJ; Sanner BM
    Wien Med Wochenschr; 2000; 150(12):249-55. PubMed ID: 11008329
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Angiotensin-converting enzyme inhibitors in preventing remodeling and development of heart failure after acute myocardial infarction: results of the German multicenter study of the effects of captopril on cardiopulmonary exercise parameters (ECCE).
    Kleber FX; Sabin GV; Winter UJ; Reindl I; Beil S; Wenzel M; Fischer M; Doering W
    Am J Cardiol; 1997 Aug; 80(3A):162A-167A. PubMed ID: 9293972
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antecedent hypertension and the effect of captopril on the risk of adverse cardiovascular outcomes after acute myocardial infarction with left ventricular systolic dysfunction: Insights from the Survival and Ventricular Enlargement Trial.
    Kenchaiah S; Davis BR; Braunwald E; Rouleau JL; Dagenais GR; Sussex B; Steingart RM; Brown EJ; Lamas GA; Gordon D; Bernstein V; Pfeffer MA;
    Am Heart J; 2004 Aug; 148(2):356-64. PubMed ID: 15309009
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.